As we are a pretty opinionated bunch here at PharmaTimes, we like it when contributors are prepared to stand up and express a viewpoint. For the past few months, our expanded SmartViews section has featured thought-leading articles on a wide range of topics – from patient-centricity and merger mania to drug pricing and product launch strategy – and this month is no exception.
In SmartViews, we offer articles on topics as diverse as the dangers of Brexit, a crisis in pharmacy, the impact of new EU clinical trial regulations and yet more threats to pharma's reputation.
Also in this issue, in Time to Think Rare, we continue our in-depth look at the challenges and opportunities in rare diseases, this month asking what patients need and how pharma can help.
Going 'beyond the pill' is a major trend in the industry yet many companies focus solely on digital innovation. In Outside the Box, we explore how the packaging and formulation of a medicine can boost sales – but only if you listen to patients first.
Translating great science into the next generation of life-changing medicines requires a leap of faith but pharma companies are getting a helping hand. In Care Package, we feature three organisations that are building early stage projects for pharma to take to market.
Going 'beyond the pill' is a major trend in pharma today, with companies seeking innovative approaches to engaging patients and driving growth. While much of the innovation comes from the digital space, there are other ways to create value for patients
Creating the next generation of life-changing medicines has always been pharma's greatest challenge, but with pipelines drying up many companies need a helping hand. We speak to three organisations doing just that – building early stage projects into packages that pharma can take to market
As one of the most efficient markets in Europe, the UK's generic medicines sector saves the NHS billions of pounds each year – but how will it cope with the arrival of biosimilars and a government intent on austerity at any cost?